Periodic Reporting for period 1 - Genome Biologics (Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry)
Reporting period: 2017-06-01 to 2017-09-30
In addition, we have identified potential interest in our technologies for lifestyle diseases, including Non-Alcoholic Fatty Liver disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), obesity and diabetes, which we are currently following up with one of the potential trial partners for a future project application in Phase 2. Investigation of the regulatory environment within Europe has not revealed any issues apart from the requirement to obtain biosafety approval from the appropriate government biosafety authorities. We have provided price indications and quotations to a number of companies and the response has been very good. All companies see the benefit of our technologies outweighing the cost and therefore are not particularly sensitive to the cost factor. These and other analyses are summarised in the Phase 1 final report.